Drug Trial Radar · NCT07873827
KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
115
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
May 12, 2028
Study completion May 12, 2030
Sponsor
- Lead sponsor
- Stemline Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
Conditions
- Hematological Malignancy
Interventions
MEN2312Drug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (28 days)
- Part A: Number of Participants Experiencing Severe ToxicityTime frame: Cycle 1 Day 1 through the completion of Cycle 4 (each cycle length = 28 days) (maximum duration: 112 days)
- Part B: Overall Response Rate (ORR) per Central Laboratory AssessmentTime frame: Up to approximately 1.5 years
- Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 1.5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.